Your browser doesn't support javascript.
loading
New Insights into Inflammatory Bowel Diseases from Proteomic and Lipidomic Studies.
Longo, Serena; Chieppa, Marcello; Cossa, Luca G; Spinelli, Chiara C; Greco, Marco; Maffia, Michele; Giudetti, Anna M.
Afiliación
  • Longo S; Department of Biological and Environmental Sciences and Technologies, University of Salento, via Monteroni 165, 73100 Lecce, Italy.
  • Chieppa M; National Institute of Gastroenterology "S. de Bellis", Institute of Research, Via Turi, 27, 70013 Castellana Grotte, Italy.
  • Cossa LG; Department of Biological and Environmental Sciences and Technologies, University of Salento, via Monteroni 165, 73100 Lecce, Italy.
  • Spinelli CC; Department of Biological and Environmental Sciences and Technologies, University of Salento, via Monteroni 165, 73100 Lecce, Italy.
  • Greco M; Department of Mathematics and Physics "Ennio De Giorgi", University of Salento, via Monteroni, 73100 Lecce, Italy.
  • Maffia M; Department of Biological and Environmental Sciences and Technologies, University of Salento, via Monteroni 165, 73100 Lecce, Italy.
  • Giudetti AM; Department of Biological and Environmental Sciences and Technologies, University of Salento, via Monteroni 165, 73100 Lecce, Italy.
Proteomes ; 8(3)2020 Aug 10.
Article en En | MEDLINE | ID: mdl-32784952
Ulcerative colitis (UC) and Crohn's disease (CD) represent the two main forms of chronic inflammatory bowel diseases (IBD). The exact IBD etiology is not yet revealed but CD and UC are likely induced by an excessive immune response against normal constituents of the intestinal microbial flora. IBD diagnosis is based on clinical symptoms often combined with invasive and costly procedures. Thus, the need for more non-invasive markers is urgent. Several routine laboratory investigations have been explored as indicators of intestinal inflammation in IBD, including blood testing for C-reactive protein, erythrocyte sedimentation rate, and specific antibodies, in addition to stool testing for calprotectin and lactoferrin. However, none has been universally adopted, some have been well-characterized, and others hold great promise. In recent years, the technological developments within the field of mass spectrometry (MS) and bioinformatics have greatly enhanced the ability to retrieve, characterize, and analyze large amounts of data. High-throughput research allowed enhancing the understanding of the biology of IBD permitting a more accurate biomarker discovery than ever before. In this review, we summarize currently used IBD serological and stool biomarkers and how proteomics and lipidomics are contributing to the identification of IBD biomarkers.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Proteomes Año: 2020 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Proteomes Año: 2020 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza